Carisma Therapeutics, OrthoCellix enter definitive merger agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2025
0mins
Should l Buy OCGN?
Merger Announcement: Carisma Therapeutics and OrthoCellix have entered into a definitive all-stock merger agreement, focusing on the development of OrthoCellix's NeoCart technology for treating knee cartilage defects, with plans to initiate a Phase 3 clinical trial by the end of 2025.
Ownership Structure and Future Plans: Following the merger, OrthoCellix stockholders are expected to own approximately 90% of the combined company, which will be renamed OrthoCellix, Inc., trading under the ticker 'OCLX,' with the transaction anticipated to close in the second half of 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCGN
Wall Street analysts forecast OCGN stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.860
Low
7.00
Averages
7.67
High
8.00
Current: 1.860
Low
7.00
Averages
7.67
High
8.00
About OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OCUGEN REPORTS Q4 NET LOSS OF USD 17.706 MILLION
- Financial Performance: OCUGEN reported a net income of USD 17.706 million for Q4.
- Quarterly Results: The financial results indicate a significant performance in the fourth quarter.
See More
Ocugen Set to Announce Q4 Earnings on March 4
- Earnings Announcement: Ocugen is set to release its Q4 earnings on March 4 before market open, with a consensus EPS estimate of -$0.06, reflecting a 20% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The anticipated revenue for Q4 is $0.86 million, representing a 13.2% year-over-year increase, indicating a gradual recovery in the company's market position that could positively influence future investment decisions.
- Performance Track Record: Over the past year, Ocugen has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating a level of stability and reliability in its financial performance that may attract investor interest.
- Stock Offering: Ocugen successfully priced a $22.5 million common stock offering at $1.50 per share, providing essential funding to support its ongoing R&D and market expansion initiatives.
See More
Ocugen Reports Q4 2025 Financial Results
- Financial Performance: Ocugen reported a GAAP EPS of -$0.06 for Q4 2025, aligning with expectations and indicating a degree of financial stability despite ongoing losses.
- Cash Position: As of December 31, 2025, Ocugen's cash and restricted cash totaled $18.9 million, a significant decline from $58.8 million on December 31, 2024, highlighting pressures in cash management.
- Funding Outlook: The company anticipates that the $22.5 million financing in January 2026 will enable it to fund operations into Q4 2026, reflecting a positive outlook on future cash flow despite current funding challenges.
- Cash Runway Extension: If the Janus Henderson warrants are fully exercised this year, it is expected that the cash runway will extend into Q2 2027, providing greater assurance for the company's long-term operational viability.
See More
OCUGEN REPORTS Q4 OPERATING EXPENSES OF $16.802 MILLION
- Operating Expenses: The operating expenses for Q4 are reported to be USD 16.802 million.
- Financial Overview: The financial data indicates a significant expenditure in the operational sector for the specified quarter.
See More
OCU400 Clinical Trial Enrollment Completed
- Trial Enrollment Completed: The liMeliGhT clinical trial for OCU400 has successfully enrolled 140 patients, reflecting strong interest from investigators and patients, marking a significant step towards potentially launching the first gene therapy candidate for RP in 2027.
- Data Release Expectations: Topline data expected in Q1 2027 will support the Biologics License Application (BLA) for OCU400, providing a new treatment option for early to late-stage retinitis pigmentosa patients and addressing a significant market gap.
- Long-term Efficacy Validation: OCU400 demonstrated approximately 2-line visual improvement over three years in Phase 1/2 trials, with 88% of treated subjects showing vision preservation or improvement, reinforcing its safety and tolerability profile and potentially shifting the treatment paradigm for RP.
- Gene-Agnostic Mechanism: This trial is the only broad gene-agnostic RP study, aiming to target multiple genetic mutations with a single therapeutic approach, showcasing OCU400's potential to offer effective treatment options for the 98% of RP patients who are not candidates for existing gene therapies.
See More
Ocugen Advances OCU400 for Retinitis Pigmentosa with FDA Submission Plans
- Innovative Treatment Approach: Ocugen is advancing OCU400, a one-time injection targeting all gene mutations associated with retinitis pigmentosa (RP), potentially offering a new treatment option for 98% of RP patients who currently lack therapy, highlighting significant market potential.
- Clinical Study Results: In a study involving 18 subjects, OCU400 demonstrated favorable safety and tolerability, with all treated subjects showing improvement or preservation in visual function after two years compared to untreated eyes, indicating substantial efficacy.
- FDA Application Plans: Ocugen plans to initiate a rolling Biologics License Application (BLA) for OCU400 this year, a process that allows for the submission of completed sections of the application to expedite approval, with a target to complete the application by the first half of 2026.
- Positive Market Reaction: Following the announcement of its FDA application plans, Ocugen's stock rose nearly 5% on Wednesday, and the stock has more than tripled over the past 12 months, reflecting strong investor confidence in the therapy.
See More
OCUGEN REPORTS Q4 NET LOSS OF USD 17.706 MILLION
- Financial Performance: OCUGEN reported a net income of USD 17.706 million for Q4.
- Quarterly Results: The financial results indicate a significant performance in the fourth quarter.
See More
Ocugen Set to Announce Q4 Earnings on March 4
- Earnings Announcement: Ocugen is set to release its Q4 earnings on March 4 before market open, with a consensus EPS estimate of -$0.06, reflecting a 20% year-over-year decline, which may impact investor sentiment.
- Revenue Expectations: The anticipated revenue for Q4 is $0.86 million, representing a 13.2% year-over-year increase, indicating a gradual recovery in the company's market position that could positively influence future investment decisions.
- Performance Track Record: Over the past year, Ocugen has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating a level of stability and reliability in its financial performance that may attract investor interest.
- Stock Offering: Ocugen successfully priced a $22.5 million common stock offering at $1.50 per share, providing essential funding to support its ongoing R&D and market expansion initiatives.
See More
Ocugen Reports Q4 2025 Financial Results
- Financial Performance: Ocugen reported a GAAP EPS of -$0.06 for Q4 2025, aligning with expectations and indicating a degree of financial stability despite ongoing losses.
- Cash Position: As of December 31, 2025, Ocugen's cash and restricted cash totaled $18.9 million, a significant decline from $58.8 million on December 31, 2024, highlighting pressures in cash management.
- Funding Outlook: The company anticipates that the $22.5 million financing in January 2026 will enable it to fund operations into Q4 2026, reflecting a positive outlook on future cash flow despite current funding challenges.
- Cash Runway Extension: If the Janus Henderson warrants are fully exercised this year, it is expected that the cash runway will extend into Q2 2027, providing greater assurance for the company's long-term operational viability.
See More
OCUGEN REPORTS Q4 OPERATING EXPENSES OF $16.802 MILLION
- Operating Expenses: The operating expenses for Q4 are reported to be USD 16.802 million.
- Financial Overview: The financial data indicates a significant expenditure in the operational sector for the specified quarter.
See More
OCU400 Clinical Trial Enrollment Completed
- Trial Enrollment Completed: The liMeliGhT clinical trial for OCU400 has successfully enrolled 140 patients, reflecting strong interest from investigators and patients, marking a significant step towards potentially launching the first gene therapy candidate for RP in 2027.
- Data Release Expectations: Topline data expected in Q1 2027 will support the Biologics License Application (BLA) for OCU400, providing a new treatment option for early to late-stage retinitis pigmentosa patients and addressing a significant market gap.
- Long-term Efficacy Validation: OCU400 demonstrated approximately 2-line visual improvement over three years in Phase 1/2 trials, with 88% of treated subjects showing vision preservation or improvement, reinforcing its safety and tolerability profile and potentially shifting the treatment paradigm for RP.
- Gene-Agnostic Mechanism: This trial is the only broad gene-agnostic RP study, aiming to target multiple genetic mutations with a single therapeutic approach, showcasing OCU400's potential to offer effective treatment options for the 98% of RP patients who are not candidates for existing gene therapies.
See More
Ocugen Advances OCU400 for Retinitis Pigmentosa with FDA Submission Plans
- Innovative Treatment Approach: Ocugen is advancing OCU400, a one-time injection targeting all gene mutations associated with retinitis pigmentosa (RP), potentially offering a new treatment option for 98% of RP patients who currently lack therapy, highlighting significant market potential.
- Clinical Study Results: In a study involving 18 subjects, OCU400 demonstrated favorable safety and tolerability, with all treated subjects showing improvement or preservation in visual function after two years compared to untreated eyes, indicating substantial efficacy.
- FDA Application Plans: Ocugen plans to initiate a rolling Biologics License Application (BLA) for OCU400 this year, a process that allows for the submission of completed sections of the application to expedite approval, with a target to complete the application by the first half of 2026.
- Positive Market Reaction: Following the announcement of its FDA application plans, Ocugen's stock rose nearly 5% on Wednesday, and the stock has more than tripled over the past 12 months, reflecting strong investor confidence in the therapy.
See More
